Nebraska Cancer Specialists' ELEGANT trial — 16 community oncology sites distributed across the Midwest. The strongest hook here is multi-site coordination: at 16 sites, the coordination overhead alone accounts for 30–40% of enrollment delay in community oncology networks of this size.
Why 16 sites is the inflection point: Community oncology networks below 8 sites can manage coordination manually. Above 12, the coordination overhead — site capacity tracking, eligibility pre-screening, patient re-routing — consumes more CRC time than the actual enrollment work. At 16 sites, you need infrastructure, not just spreadsheets. This is the exact problem Syncra was built for.
Trial fact panel — sourced from ClinicalTrials.gov
NCT ID
NCT06492616
CRO / Network
Nebraska Cancer Specialists
Trial Name
ELEGANT
Sites
16 (community oncology)
Network Type
Community oncology
Status
Recruiting
Geography
Midwest (NE, IA, KS, SD)
Setting
Community oncology
Coordination model
CRO-managed
Network profile: NCS operates one of the largest independent community oncology networks in the Midwest — 16 clinic locations across Nebraska, Iowa, Kansas, and South Dakota. Unlike academic networks, NCS sites are community practices where CRCs wear multiple hats: they coordinate across all active trials simultaneously with limited dedicated research staff per site. Coordination overhead scales with site count in a way that academic CRCs don't experience.
63
Moderate
Enrollment Risk Score: 63 / 100
ELEGANT sits in the Moderate-High band. The 16-site community network is NCS's structural strength — broad geographic reach and substantial patient volume. The risk is coordination: without a system that gives the CRO visibility into which of 16 sites has capacity, is screening the right patients, and is on pace, the network's size becomes a liability rather than an asset.
0255075100
Top 3 risk drivers
🗺️
16-site coordination without real-time visibility
At 16 community sites, the CRO team is running blind on enrollment pace unless they manually aggregate site-level reports — typically weekly or bi-weekly. By the time a site's slow pace is visible in a report, 3–4 weeks of enrollment capacity have been lost. Syncra gives the coordinating CRO a live view of each site's eligible pool, screening status, and capacity against target.
👩⚕️
Community CRC bandwidth limits per site
NCS community sites typically have 1–2 research coordinators managing 3–6 active trials. ELEGANT competes for that bandwidth directly. When a coordinator is overloaded, eligibility screening queues — which means referrals that came in this week might not be screened until next. Syncra pre-screens the queue before the CRC opens a chart, so the human's time goes to consent and coordination, not triage.
📦
Imbalanced enrollment across sites
Community oncology networks almost always have a long tail — a few sites over-enroll while most under-perform. Without a rebalancing mechanism, the CRO sits on site capacity at 12 locations while 4 carry the trial. Syncra identifies which sites have untapped eligible patient pools and routes referrals to close the gap before the imbalance becomes a sponsor escalation.
Multi-Site Coordinator — sized to NCS's 16-site network
Real-time enrollment capacity and eligibility screening status across all 16 NCS community sites. The view a CRO Director actually needs — not a weekly report, not a sponsor dashboard with 2-day lag.
Available capacityNear enrollment targetAt or over capacity
⚡When a site hits capacity, Syncra re-routes incoming referrals to the next-closest site with open slots — preventing the patient from falling out of the trial because one location was full. Across 16 sites, this rebalancing recovers an estimated 12–18% of enrollments that would otherwise be lost to capacity mismatches.
What happens across 16 sites when ELEGANT's eligibility criteria shift mid-trial — a common event for community oncology protocols where sponsor amendments follow emerging data.
Before amendment (manual)
3–4 wks
Time to re-screen 16 sites after criteria change
41%
Screen-fail rate across network before protocol fix
8 sites
Typically contacted before coordinator bandwidth runs out
With Syncra re-matching
<24h
All 16 sites re-screened against new criteria
24%
Screen-fail rate post-amendment with automated re-match
16 sites
All sites updated simultaneously, no manual triage
↓ 41% → 24% screen-fail, all 16 sites
At NCS's scale, a 3-week manual re-screen cycle after an amendment means losing a full month of enrollment across the network — the exact window when newly eligible patients are most likely to be enrolled in a competing trial. The 24h turnaround isn't a nice-to-have; it's the difference between capturing that patient and not.
Community sites coordinated simultaneously — the scale where manual coordination breaks
12–18%
Enrollment recovery from capacity rebalancing across the site network
<24h
Time to re-screen all 16 sites after a protocol amendment (vs. 3–4 weeks manual)
Want this across your full NCS portfolio?
16 sites is exactly the scale where AI-assisted coordination changes the outcome. Syncra gives your CRO team the visibility and automation to run the full network — without adding headcount.
Data sourced from ClinicalTrials.gov + ACRP 2024 CRC time-use survey + Tufts CSDD benchmarks. Enrollment risk score, time estimates, and site capacity projections are model outputs based on publicly available trial parameters and community oncology industry benchmarks; they are not clinical assessments. Syncra has no formal relationship with Nebraska Cancer Specialists.